Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• mRNA vaccines (BNT162b2, mRNA-1273) are effective in immunocompetent individuals against COVID-19.
• Patients with chronic lymphocytic leukemia (CLL) exhibit a diminished humoral immune response to SARS-CoV-2 vaccines compared to the general population.
• This reduced response is attributed to the CLL disease process and immunosuppressive therapies.

Purpose of the Study:

• To highlight the suboptimal vaccine response in chronic lymphocytic leukemia (CLL) patients.
• To propose strategies for improving COVID-19 vaccine efficacy in CLL.
• To identify patient groups requiring alternative preventive measures.

Main Methods:

• Review of cohort studies and meta-analyses on SARS-CoV-2 vaccine responses in CLL.
• Analysis of factors contributing to inadequate humoral immunity in CLL patients.
• Consideration of clinical trial designs for vaccine optimization.

Main Results:

• Chronic lymphocytic leukemia (CLL) patients demonstrate lower antibody titers post-vaccination.
• Disease activity and immunosuppressive treatments significantly impair vaccine effectiveness.
• Hypogammaglobulinemia is a common and serious complication in CLL patients.

Conclusions:

• Clinical trials are essential to determine optimal vaccination schedules and booster timing for CLL patients, particularly those on targeted therapies.
• Patients with undetectable antibody responses should be considered for prophylactic antibody therapy.
• Further research is needed to enhance vaccine-induced immunity in immunocompromised individuals with hematological malignancies.